Well, I like EnVivo's trials better due to the ability to see dose related responses especially in AD trial - their schizophrenia trial was more mixed in this regard. TRGT used one single dose titration schedule, result wasn't clear cut, no surprise AZN declined. These are tough indications, even clear cut positive ph2 data don't necessarily replicate in larger ph3. High risk programs IMO. I need to read more about the target to get better feel about these trials. AD trial result is interesting though.
Market Data 
Markets 
AI
